Page 71 - எங்களுக்கு தேசிய நிறுவனம் ஆஃப் ஒவ்வாமை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Science s COVID-19 reporting is supported by the Heising-Simons Foundation The questions are urgent, and the funding is in place. But a highly anticipated, $130 million clinical trial, meant to test the efficacy of the novel messenger RNA (mRNA) vaccines for COVID-19 against a key variant of the pandemic coronavirus as well as in people living with HIV and pregnant women, is stalled. It is ready to launch in eight countries in sub-Saharan Africa, yet neither maker of the vaccines, Pfizer and Moderna, wants to participate or even provide their vaccines. A group of prominent HIV advocates and activists in South Africa has written a letter complaining about the delay to U.S. government officials, including Anthony Fauci, director of the U.S. National Institute of Allergy and Infectious Diseases (NIAID), which agreed to pay for the study. They stress that COVID-19 strikes people living with HIV especially hard, and that dangerous variants of SARS-CoV-2 evolve in them because many have

United statesSouth africaSouth africanLawrence coreyAnthony fauciLinda gail bekkerGlenda grayHeising simons foundationWorld health organizationUs national institute of allergyPrevention networkAfrican medical research councilFred hutchinson cancer research centerSaharan africaInfectious diseasesSouth african medical research council